SYBX

Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease

Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Synlogic to Present at Upcoming Virtual Banking and Industry Conference

Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease

Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript

Synlogic Reports First Quarter Financial Results and Provides Business Update

Synlogic Announces Pricing of Public Offering of Common Stock